|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions |
ISO |
[arsenic trioxide results in increased susceptibility to PD 173074] which results in decreased expression of BIRC5 protein |
CTD |
PMID:27794399 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
[PKI 166 co-treated with PD 173074] results in decreased expression of CCND1 protein |
CTD |
PMID:15377668 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
multiple interactions |
ISO |
PD 173074 inhibits the reaction [FGF1 protein results in increased phosphorylation of FGFR4 protein] |
CTD |
PMID:15709206 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
decreases activity multiple interactions decreases expression |
ISO |
PD 173074 results in decreased activity of FGFR1 protein [PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein]; Arsenic Trioxide promotes the reaction [PD 173074 results in decreased expression of FGFR1 protein]; PD 173074 promotes the reaction [Arsenic Trioxide results in decreased expression of FGFR1 protein] |
CTD |
PMID:22683780 PMID:27794399 |
|
NCBI chr16:66,492,445...66,546,731
Ensembl chr16:66,494,042...66,547,350
|
|
G |
Fgfr3 |
fibroblast growth factor receptor 3 |
decreases activity |
ISO |
PD 173074 results in decreased activity of FGFR3 protein |
CTD |
PMID:15029211 |
|
NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341
|
|
G |
Fgfr4 |
fibroblast growth factor receptor 4 |
multiple interactions decreases activity |
ISO |
PD 173074 inhibits the reaction [FGF1 protein results in increased phosphorylation of FGFR4 protein] PD 173074 results in decreased activity of FGFR4 protein |
CTD |
PMID:15377668 PMID:15709206 |
|
NCBI chr17:9,461,541...9,476,268
Ensembl chr17:9,461,547...9,476,242
|
|
G |
Hgf |
hepatocyte growth factor |
multiple interactions |
ISO |
[PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] |
CTD |
PMID:22683780 |
|
NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation multiple interactions decreases expression |
ISO |
PD 173074 results in decreased phosphorylation of MAPK1 protein PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK1 protein] PD 173074 results in decreased expression of MAPK1 protein |
CTD |
PMID:15029211 PMID:25953896 PMID:27794399 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation multiple interactions decreases expression |
ISO |
PD 173074 results in decreased phosphorylation of MAPK3 protein PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK3 protein] PD 173074 results in decreased expression of MAPK3 protein |
CTD |
PMID:15029211 PMID:25953896 PMID:27794399 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
multiple interactions |
ISO |
[PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] |
CTD |
PMID:22683780 |
|
NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
[arsenic trioxide co-treated with PD 173074] results in increased expression of PARP1 protein modified form; [arsenic trioxide results in increased susceptibility to PD 173074] which results in increased expression of PARP1 protein modified form; [PD 173074 results in increased susceptibility to arsenic trioxide] which results in increased expression of PARP1 protein modified form |
CTD |
PMID:27794399 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Phlpp1 |
PH domain and leucine rich repeat protein phosphatase 1 |
multiple interactions |
ISO |
PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK1 protein]; PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:25953896 |
|
NCBI chr13:22,308,532...22,530,978
Ensembl chr13:22,308,548...22,530,977
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
decreases expression multiple interactions |
ISO |
PD 173074 results in decreased expression of RAF1 protein; PD 173074 results in decreased expression of RAF1 protein modified form [arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein; [arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein modified form; [arsenic trioxide results in increased susceptibility to PD 173074] which results in decreased expression of RAF1 protein; [PD 173074 results in increased susceptibility to arsenic trioxide] which results in decreased expression of RAF1 protein; [PD 173074 results in increased susceptibility to arsenic trioxide] which results in decreased expression of RAF1 protein modified form; arsenic trioxide promotes the reaction [PD 173074 results in decreased expression of RAF1 protein modified form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein modified form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein] |
CTD |
PMID:27794399 |
|
NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
ISO |
[PKI 166 co-treated with PD 173074] results in decreased activity of RPS6KB1 protein |
CTD |
PMID:15377668 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions decreases expression |
ISO |
[Arsenic Trioxide co-treated with PD 173074] results in decreased expression of SRC protein; [Arsenic Trioxide results in increased susceptibility to PD 173074] which results in decreased expression of SRC protein; [PD 173074 results in increased susceptibility to Arsenic Trioxide] which results in decreased expression of SRC protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Arsenic Trioxide co-treated with PD 173074] results in decreased expression of SRC protein]; PD 173074 promotes the reaction [Arsenic Trioxide results in decreased expression of SRC protein modified form]; PD 173074 promotes the reaction [Arsenic Trioxide results in decreased expression of SRC protein] PD 173074 results in decreased expression of SRC protein; PD 173074 results in decreased expression of SRC protein modified form |
CTD |
PMID:27794399 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Tbx3 |
T-box transcription factor 3 |
multiple interactions |
ISO |
PD 173074 inhibits the reaction [afimoxifene results in increased expression of TBX3 protein]; PD 173074 inhibits the reaction [Estrogens results in increased expression of TBX3 protein] |
CTD |
PMID:21098263 |
|
NCBI chr12:36,879,924...36,894,849
Ensembl chr12:36,881,445...36,893,708
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide promotes the reaction [PD 173074 inhibits the reaction [Sodium Chloride results in increased expression of VEGFA mRNA]]; PD 173074 inhibits the reaction [Sodium Chloride results in increased expression of VEGFA mRNA] |
CTD |
PMID:26800359 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|